<?xml version="1.0" encoding="UTF-8"?>
<p>While several studies and research work have explored different anticancer activities for diverse fused pyridazine derivatives, little attention has been paid to investigate the anticancer activity for the non-fused 3,6-disubstituted pyridazine derivatives over the last two decades
 <xref rid="CIT0021" ref-type="bibr">
  <sup>21–30</sup>
 </xref>. For example; compound 
 <bold>I</bold> (
 <xref ref-type="fig" rid="F0002">Figure 2</xref>) displayed potent 
 <italic>in vitro</italic> and 
 <italic>in vivo</italic> antitumor and anti-angiogenesis activities
 <xref rid="CIT0021" ref-type="bibr">
  <sup>21</sup>
 </xref>, compound 
 <bold>II</bold> (
 <xref ref-type="fig" rid="F0002">Figure 2</xref>) efficiently inhibited the cell proliferation in a panel of breast, colon, prostate and liver human tumours
 <xref rid="CIT0028" ref-type="bibr">
  <sup>28</sup>
 </xref>. In addition, compound 
 <bold>III</bold> (
 <xref ref-type="fig" rid="F0002">Figure 2</xref>) elicited excellent cytotoxic activity towards human colon cancer HT-29 cell line
 <xref rid="CIT0022" ref-type="bibr">
  <sup>22</sup>
 </xref>, whereas compound 
 <bold>IV</bold> (
 <xref ref-type="fig" rid="F0002">Figure 2</xref>) emerged as promising VEGFR-2 inhibitor with IC
 <sub>50</sub> in the nanomolar range
 <xref rid="CIT0029" ref-type="bibr">
  <sup>29</sup>
 </xref>.
</p>
